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A mean residence time (MRT) is an important pharmacokinetic parameter. To the author’s knowledge, however, a physiologically
based structure of MRT (thereafter MRT structure) has not been published so far. Primarily this is because MRT structures cannot
beidentiﬁedbytraditionalpharmacokineticmethodsusedforthedeterminationofMRT.Therefore,toolsfromthetheoryoflinear
dynamic systems were used for the structural identiﬁcation of MRT in this study. The MRT structure identiﬁed is physiologically
meaningful. Accordingly, it seems that the MRT structure identiﬁed may contribute to already established knowledge about MRT.
1.Introduction
A mean residence time (MRT) is an important pharmacoki-
netic parameter. However, to the author’s knowledge, a phys-
iologically based structure of MRT (thereafter MRT struc-
ture) has not been published so far. Primarily this is because
MRT structures cannot be identiﬁed by traditional phar-
macokinetic methods, commonly used to determine MRT.
Therefore, tools from the linear dynamic system theory were
used for the structural identiﬁcation of MRT in this study
[1].
Drug disposition is a composite procedure arising from
thecomplexityanddiversityofinteractionsbetweenthedrug
administered, physiological mechanisms, and various exoge-
nousfactors.Furthermore,drugdispositioniscontrolledtoa
greater extent by several dynamic pharmacokinetic processes
[2]. For that reason, several studies described investigations
of drug disposition with the aid of dynamic systems,
using the following steps: (1) a construction of an ADME-
related dynamic system, (2) a development of a mathe-
matical model of the system constructed, for example, [3–
7]. ADME-related dynamic systems are mathematical con-
structs (working tools) without any pharmacokinetic rele-
vance. The meaning of the acronym ADME is explained in
many pharmacokinetic studies, for example, [8]. In the
presentstudy,theADME-relateddynamicsystemwassimply
called the system.
There are the following highly signiﬁcant diﬀerences
in terminology between pharmacokinetics and this study,
which may trigger misunderstanding for readers: The dif-
ference between the physiological nature of information
conveyed bya physiologicalsystemand the functionalnature
ofinformationconveyedbythesystemusedinthisstudy.The
diﬀerence in the use of the term “dynamic”. In pharmacoki-
netics, the term “dynamic” is commonly used in expressions
describing drug actions. In this study, the term “dynamic”
was used to indicate that the system or process changes over
time.
2. Methods
ThestructuralidentiﬁcationofMRTwasperformedemploy-
ing these steps.
(1) The introduction of the following approximate as-
sumptions: an instantaneous mixing of the drug with blood,
a uniform drug distribution [9]. A linear drug disposition
[9–11]. The liver is the only eliminating organ of signiﬁcance
for the drug administered [12].
(2)Theuseofthemethoddescribedpreviously[4,7]and
a theoretical example in which it was assumed that the drug
wasadministeredinanintravenousbolusdosetoahypothet-
ical subject.
(3) The formalization of drug disposition using the sys-
tem Hiv, created with the following conﬁguration: the drug
administration was considered as an input to the system Hiv,
and the concentration-time proﬁle of the drug in arterial
blood was considered as an output of the system Hiv.2 The Scientiﬁc World Journal
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Figure 1: Circulatory model of the system Hiv describing drug
disposition in a human body after an intravenous bolus dose of a
drug.ThedrugadministrationisdenotedbyIiv.Theconcentration-
time proﬁle of the drug in arterial blood denoted with CA.T h e
concentration-time proﬁle of the drug in venous blood denoted
with CV. The cardiopulmonary subsystem, describing the drug
transport through the heart and lungs, is denoted by Hcp.H p is
the portal-venous subsystem describing the portal transport of the
drug. Hh is the hepatic-portal subsystem describing the hepatic
transportofthedrug.Ho isthesubsystemdescribingthedrugtrans-
portthroughnoneliminatingtissues.Hr isthesubsystemdescribing
the enterohepatic cycling. The subsystem Hr i ss h o w nb yad o t t e d
line, to indicate that the enterohepatic cycling is not always present.
The symbol ⊗ denotes a summation operator. Qcp, Qp, Qh, Qo are
blood ﬂows in the subsystems speciﬁed by the subscripts.
(4)Thedevelopmentofacirculatorymodelofthesystem
Hiv, taking into account the fact that drug disposition can be
regarded as a result of repetitive passes of the drug around
the blood circulation, for example, [10, 13–16].
(5) The determination of the transfer function Hiv(s)o f
the system Hiv,f o re x a m p l e ,[ 3–7].
(6) The derivation of the general equation (1) for the
determination of MRT:
MRT =
lims→0(dHiv(s)/ds)
lims→0Hiv(s)
,( 1 )
using the transfer function Hiv(s)( s is the Laplace variable)
and all assumptions made until now, for example, [3–7, 11].
(7) The use of the general equation (1), the circulatory
model developed, and the method described previously [4]
to identify the MRT structure.
3. Results andDiscussion
The developed circulatory model of the system Hiv is
depicted in Figure 1. As seen, major body organs are lumped
into subsystems of the system Hiv, that is, into somewhat
independent parts of the system Hiv,f o re x a m p l e ,[ 13–17].
The model takes into account the fact that drug disposition
can be regarded as a result of repetitive passes of the drug
around the blood circulation, for example, [10].
The identiﬁcation of the MRT structure revealed the
presence of ﬁve structural components of MRT, which were
denoted by Fcp, Fp, Fh, Fo, Fr. The structural components
relate directly to the drug transport to the blood circulation
throughthefollowingsubsystems:thecardiopulmonarysub-
system Hcp [18], the corresponding structural component is
Fcp, the portal-venous subsystem Hp [19], the corresponding
structural component is Fp, the hepatic-portal subsystem
Hh [20], the corresponding structural component is Fh, the
subsystem Ho describing drug disposition in noneliminating
tissues [21], the corresponding structural component is Fo,
the subsystem Hr, if the drug is subject to the enterohepatic
cycling (EHC), for example, [22, 23], the corresponding
structural component is Fr.
If the drug is not subject to the EHC, the structural
component Fcp can be described as
Fcp =
Qcp
Clh
MTcp,( 2 )
whereQcpisthebloodﬂowinthesubsystemHcp,MT cpisthe
mean time of the drug transport through the subsystem Hcp,
and Clh is the hepatic clearance. The structural components
Fp, Fh,a n dFo can be described as
Fp =
Qh −Clh
Clh
Qp
Qh
MTp,
Fh =
Qh −Clh
Clh
MTh,
Fo =
Qo
Clh
MTo.
(3)
Inequationsabove,Qp isthebloodﬂowintheportalvein,Qo
is the blood ﬂow in noneliminating tissues, MTp is the mean
timeofthedrugtransportthroughthesubsystemHp,MT h is
the mean time of the drug transport through the subsystem
Hh,a n dM T o is the mean time of the drug transport through
the subsystem Ho,w h e r e
MTo =
q
i=1Qi ·MTi
Qo
,
Qo =
q 
i=1
Qi.
(4)
MTi is the mean time of the drug transport through a
noneliminating tissue; the i subscript speciﬁes the tissue
[24, 25]. If the drug is subject to the EHC, the structural
component Fr can be described as
Fr = fr
Qh −Clh
Qh − frClh

MTp +MT h +MT r

,( 5 )
where MTr is the mean time of the drug transport through
the subsystem Hr, and the coeﬃcient fr,0≤ fr < 1, deter-
mines the fraction of the drug that is the subject to the EHC.
The resulting equation (6) describes the MRT structure
identiﬁed
MRT = Fcp+Fp +Fh +Fo +Fr. (6)The Scientiﬁc World Journal 3
From the text above it evident that the right-hand side of the
resulting equation (6) is the sum of (2)–(5). Equation (6)
looks mathematically elegant and very simple. Nevertheless,
this equation provides a mathematical description of the
physiologically based structure of the mean residence time of
the drug administered as the intravenous bolus to the subject
(here to the hypothetical subject, as speciﬁed above).
The transfer function Hiv(s) used in the general equation
(1) is the mathematical relationship between the output and
input of the system Hiv. Generally, transfer functions are
characteristic functions of linear dynamic systems, providing
complete descriptions of linear dynamic systems in the
Laplace domain, for example, [3–5].
It is well known that, after an intravenous administra-
tion, a total amount of a drug is fully and immediately
available to the blood circulation for transports to all areas
of the body, a drug is not destroyed by digestive enzymes, an
intravenous administration oﬀers an advantage over other
routes of administration in its accuracy. The purpose of
recalling these well-known facts is to explain why the as-
sumptionoftheintravenousdrugadministrationwasusedin
the theoretical example in this study.
The circulatory model developed possesses properties of
simplicity and accuracy to describe the disposition of the
drug administered as the intravenous bolus to the subject.
The properties of the model make the model very ﬂexible
because the model is highly capable of accurately describing
drug disposition in both situations, that is, when the drug
is subject to the EHC and also when the drug is not
subject to the EHC. This indicated that the model is very
suitable for identifying the MRT structure. The model is very
general and appears applicable to several drugs. Using the
model, the equations (2)–(6) were determined. Equations
(2)–(6) can contribute to understanding mechanisms that
control MRT, they can be used to reﬁne already established
knowledgeofMRT,andcanhelptogainfurtherinsightsinto
physiological background of MRT. The equations (2)–(6)
are easy to handle and may be suﬃcient in pharmacokinetic
studies.Primarilythisisbecausetheseequationsarebasedon
the commonly available physiological and pharmacokinetic
knowledge.
The MRT structure identiﬁed in this study has not been
experimentally validated up to now. Its validity can be ver-
iﬁed by further investigations, mainly experimental investi-
gations; consequently a full pharmacokinetic exploitation of
the MRT structure identiﬁed lies far in the future.
For the sake of conciseness, mathematical details were
restricted to a bare minimum. Diﬀerences between tradi-
tional pharmacokinetic approaches to MRT and the ap-
proach presented in this study were left unexplained. Instead
of a comparison of the approaches, this study gives rise to
a reasonable expectation that the MRT structure identiﬁed
may be useful for basic research in pharmacokinetics. This is
because the MRT structure identiﬁed may reveal features of
MRT not apparent from MRT values routinely determined
by traditional methods which integrate inﬂuences of several
processes in the body on MRT into single numerical quan-
tities, not providing any information about physiological
backgrounds of MRT.
4. Conclusion
This study presented a new view on “old” principles asso-
ciated with MRT. It attempted to contribute to the current
understanding of MRT, without an intention to criticize
traditional approaches to MRT. According to the best of the
author’s knowledge, and after a Medline search, it can be
stated that a physiologically based structure of MRT has not
been described in the literature as yet.
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